The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi-institutional cohort study.

Sho SatoYoko OshimaYu MatsumotoYasuyuki SetoHiroharu YamashitaKoichi HayanoMasayuki KanoHidetaka Andrew OnoNorio MitsumoriMuneharu FujisakiChikara KunisakiHirotoshi AkiyamaItraru EndoYasushi IchikawaHidejiro UrakamiHirokazu KuboSakae NagaokaHideaki Shimada

Published in: Annals of gastroenterological surgery (2021)

Nivolumab showed safety and survival benefits in patients with previously treated unresectable or recurrent gastric cancer. Low C-reactive protein level, irAE occurrence, high albumin level, high lymphocyte count, and differentiated histological type may affect outcomes. The presence of four or more good prognostic factors may help identify likely long-term survivors.

Keyphrases

prognostic factors
locally advanced
liver metastases
peripheral blood
risk assessment
type diabetes
squamous cell carcinoma
skeletal muscle
newly diagnosed